Table 1.
Demographic characteristics and clinical laboratory values in patients with cystic fibrosis during the preliminary visit and after 4 wk of sildenafil treatment
| Variable | Preliminary Visit | 4-wk Sildenafil | P Value |
|---|---|---|---|
| Demographic characteristics | |||
| n | 15 | ||
| Sex (male/female patients), n | 8/7 | ||
| Age, yr | 23 ± 11 | ||
| Height, cm | 160 ± 13 | ||
| Weight, kg | 54 (17) | 54 (17) | 0.945 |
| Body mass index, kg/m2 | 20.4 (4.0) | 20.6 (3.9) | 0.921 |
| Body fat, % | 28.5 (7.9) | 28.5 (8.0) | 0.934 |
| O2 saturation, % | 98 (1) | 98 (1) | 0.670 |
| Systolic blood pressure, mmHg | 108 (11) | 110 (10) | 0.274 |
| Diastolic blood pressure, mmHg | 65 ± 7 | 68 (4) | 0.090 |
| Pulmonary function | |||
| FVC, liters | 3.35 (0.92) | 3.36 (0.93) | 0.986 |
| FEV1 | |||
| Liters | 2.59 (0.83) | 2.64 (0.84) | 0.563 |
| %Predicted | 80 (16) | 81 (14) | 0.588 |
| FEV1/FVC, % | 77 (8) | 76 (7) | 0.741 |
| FEF25–75, l/s | 2.41 (1.28) | 2.29 (1.32) | 0.354 |
| Clinical laboratory values | |||
| Total cholesterol, mg/dl (<200 mg/dl) | 134 (33) | 139 (31) | 0.257 |
| High-density lipoprotein, mg/dl (>40 mg/dl) | 42 (12) | 47 (10) | 0.194 |
| Low-density lipoprotein, mg/dl [<130 mg/dl] | 72 (28) | 75 (30) | 0.486 |
| Triglycerides, mg/dl (<150 mg/dl) | 99 (39) | 84 (31) | 0.179 |
| Total cholesterol/high-density lipoprotein (<5) | 3.5 (1.0) | 3.3 (1.1) | 0.756 |
| Glucose, mg/dl (70–110 mg/dl) | 97 (18) | 95 (12) | 0.711 |
| Hemoglobine A1c (<6%) | 5.5 (0.4) | 5.6 (0.5) | 0.426 |
| High-sensitivity C-reactive protein, mg/l (<3 mg/l) | 2.7 (4.9) | 1.4 (1.7) | 0.361 |
| Hemoglobin, g/dl (12–18 g/dl) | 14.7 (1.9) | 14.7 (2.0) | 0.989 |
| Hematocrit, % (37–54%) | 44.1 (4.0) | 44.5 (4.2) | 0.607 |
Values are means (SD). Clinical laboratory values reference ranges are denoted in parentheses. FVC, forced vital capacity, FEV1, forced expiratory volume in 1 s; FEF25–75, forced expiratory flow at 25–75% of pulmonary volume.